Drug
Efatutazone
Efatutazone: highest development phase Phase 2, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| efatutazone NCT02249949 | Phase 2 | Liposarcoma |
Latest
No recent events.
Follow Efatutazone on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.